68-Gallium-DOTATATE-PET/CT
Phase 2
68-Gallium-DOTATATE-PET/CT is one of 6 therapeutic programs targeting Thyroid Carcinoma. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
7 competitors in Thyroid Carcinoma
#DrugCompanyPhaseTrials
1Lenvima
EisaiApproved
Anlotinib Hydrochloride
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 3
Lanoxin
AAdvanz Pharma
Preclinical
Tirosint
IInstitut Jerome Lejeune
Preclinical
68-Gallium-DOTATATE-PET/CT
NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase 2
Iodine-124
SStanford University
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Thyroid Carcinoma1 trial
The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer
Recruiting·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT04927416·54 enrolled
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for 68-Gallium-DOTATATE-PET/CT. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2[1]